Where are legislative trends pointing on biopharmaceutical patents? Sona De, a partner at Sidley, reviews existing proposals ...

Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, Claris Bio is rewriting the ophthalmology rulebook. CEO Clarke Atwell acknowledges that it's not ...

Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the ...

Local market pharmacovigilance (PV) requirements can be daunting to manage successfully. Experts at PharmaLex provide best ...

Looking back, I’ve made many choices in my work life that seemed crazy to my peers. In my experience, we talk a lot in America about family coming first. But if you look at how many of us organize our ...

"A version of this article was published first on Hyman, Phelps & McNamara’s FDA Law Blog. It is republished here with permission." In November, President-Elect Trump announced his pick of Robert ...

For life sciences organizations, the in-house legal function plays a strategic role, handling everything from corporate contracting to patent management, tech transfers, litigation and M&A. But in ...

Key innovation, technology, dealmaking and policy considerations are reshaping the industry’s future While patent expirations of $300b will continue to put pressure on growth, robust innovation likely ...

In life sciences, where innovation and unpredictability go hand in hand, a straight-line career path is the exception rather than the rule. The industry often demands quick pivots, complex ...

The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program — it’s a mouthful. And, if we don’t act now, it will sunset at the end of the year. I care. Why should you? Rare diseases impact ...